Kodiak Sciences Inc.
2631 Hanover Street
Palo Alto
CA
94304
United States
Tel: 650281-0810
64 articles with Kodiak Sciences Inc.
-
Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting
7/24/2019
Initial Phase 1b data for KSI-301 in Wet AMD, DME, and RVO to be presented
-
Kodiak Sciences to Present at the Jefferies 2019 Healthcare Conference
5/31/2019
Kodiak Sciences Inc. announced that management will present at the Jefferies 2019 Healthcare Conference in New York, NY on Thursday, June 6 at 2:00 p.m. Eastern Time.
-
Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights
5/15/2019
Kodiak Sciences Inc. reported business highlights and financial results for the first quarter ended March 31, 2019.
-
Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference 2019
5/9/2019
Kodiak Sciences Inc. announced that management will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV on Wednesday, May 15, at 5:00 p.m. Pacific Time.
-
Kodiak Sciences Announces Presentations at ARVO 2019 Annual Meeting
4/25/2019
Kodiak Sciences Inc. announced that presentations on its research will be made at the Association for Research in Vision and Ophthalmology 2019 Annual Meeting, being held from April 28 – May 2 in Vancouver, Canada.
-
Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
3/28/2019
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, reported business highlights and financial results for the fourth quarter and full year ended December 31, 2018.
-
The San Francisco Business Times recently looked at top alumni from Bay Area incubators. Some of those companies are now brand-name companies like Uber and Reddit. Here’s a look at the biotech companies on their list.
-
Kodiak Sciences Announces Upcoming Presentation of KSI-301 12-Week Phase 1a Study Data at Angiogenesis, Exudation, and Degeneration 2019 Meeting
2/8/2019
Kodiak Sciences Inc. announced that a presentation on its investigational therapy KSI-301 will be made at the Angiogenesis, Exudation, and Degeneration 2019 meeting being held on February 9, 2019 in Miami, FL.
-
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
-
Kodiak Sciences Added to Russell 2000®, 3000® and Microcap® Indexes
12/24/2018
Kodiak Sciences Inc. today announced that it has been added to the Russell 2000®, 3000® and Microcap® Indexes, effective as of the open of the U.S. markets on Monday, December 24, 2018.
-
Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate
12/21/2018
Rapid high-magnitude and durable treatment responses were seen at all dose levels tested in a heavily pre-treated Phase 1 patient population.
-
Kodiak Sciences Announces Third Quarter 2018 Financial Results and Recent Business Highlights
11/16/2018
Kodiak Sciences Inc.today reported business highlights and financial results for the third quarter ended September 30, 2018.
-
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
-
A Look Back at October Life Sciences IPOs
10/31/2018
October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month. -
Kodiak Sciences Inc. Announces Closing of Initial Public Offering
10/10/2018
Kodiak Sciences Inc. today announced the closing on October 9, 2018 of its initial public offering of 9,000,000 shares of common stock at a price to the public of $10.00 per share.
-
Kodiak Sciences Inc. Announces Pricing of Initial Public Offering
10/4/2018
Kodiak Sciences Inc. today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $10.00 per share.
-
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
-
Kodiak Sciences Inc. Announces Launch of Initial Public Offering
9/24/2018
Kodiak Sciences Inc. today announced that it has launched an initial public offering of 9,000,000 shares of its common stock at an anticipated initial offering price between $13.00 and $15.00 per share
-
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
-
Kodiak Sciences Files Registration Statement for Proposed Initial Public Offering
9/7/2018
Kodiak Sciences Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.